3 Biotech Stocks With Upside Of Up To 80%

Tech heavy indices have taken a hit as investors question huge AI spending, which leaves many traders searching for growth stories that are tied less to data centers and more to hard science. That is where high risk, high potential biotech stocks with solid finances come into focus. This article walks through three such biotech stocks screened for balance sheet strength and valuation discipline.

The three highlighted biotech stocks are only a sample of what screens well on balance sheet strength and value, with the full filter surfacing 86 more companies that carry similarly compelling stories that are not covered here. To go beyond the short list and identify your own highest conviction ideas, head straight into the Biotech Stocks screener to filter, analyze, and focus on the biotech setups that best fit your risk tolerance.

Overview: Jazz Pharmaceuticals develops and sells specialty therapies for sleep disorders, rare epilepsies, and cancers, anchored by marketed biotech drugs and late stage biologics.

Operations: Jazz generates about US$4.6b from pharmaceutical products, with roughly US$4.1b from the United States and the rest mainly from Europe.

Market Cap: US$13.5b

Jazz Pharmaceuticals matters for this biotech screen because it mixes a broad neurology and oncology drug toolkit with late stage assets that can meaningfully move the needle if clinical and commercial execution hold together.

“Expected expansion of Ziihera across additional HER2 driven tumors, including biliary tract, colorectal, lung and early or metastatic breast cancer, following the raised US$3b to US$5b peak sales outlook, could add new oncology revenue streams and support higher long term earnings power.”

The real swing factor is how one pressure on future cash generation interacts with everything investors currently assume about pricing and margins.

That pressure point is exactly what the full narrative for Jazz Pharmaceuticals unpacks, showing how cash flows, pipeline risk, and any Ziihera upside could be separating from headline expectations.

Overview: Arrowhead Pharmaceuticals develops RNA interference medicines, with Plozasiran and Zodasiran as late stage cardiometabolic RNAi drugs anchoring its biotech pipeline.

Operations: Arrowhead generates about US$669 million in Nanotechnology revenue, all reported from the United States, reflecting a single segment profile.

Market Cap: US$8.5b

Arrowhead Pharmaceuticals matters in this Biotech Stocks screen because its RNAi cardiometabolic pipeline offers genuine high risk, high reward drug optionality backed by a funded development plan.

“Arrowhead Pharmaceuticals has acquired an FDA Priority Review Voucher for plozasiran in severe hypertriglyceridemia and expects a second quarter 2027 launch after submitting the supplemental filing by year end 2026.”

How a single, often unstated assumption about this cardiometabolic launch and its impact on pricing power and physician behavior plays out, in either direction, could prove crucial.

If that assumption is even partly right, the full narrative for Arrowhead Pharmaceuticals maps how Arrowhead Pharmaceuticals risk, timelines, and cardiometabolic upside could be decoupling from consensus expectations.

Overview: Johnson & Johnson is a diversified healthcare group, with its biotech linked Innovative Medicine division developing prescription therapies across major diseases.

Operations: Johnson & Johnson generates about US$99.3b in revenue, with roughly US$64.3b from Innovative Medicine and US$35.0b from MedTech across global regions.

Market Cap: US$662.5b

For biotech focused investors, Johnson & Johnson matters because the Innovative Medicine arm packages cancer, immunology, and neuroscience drugs inside a much broader healthcare giant. This gives exposure to high risk R&D without relying solely on one therapy or franchise.

“Johnson & Johnson anticipates accelerated growth in their portfolio and pipeline, particularly in the Innovative Medicine sector, despite the headwind from STELARA’s loss of exclusivity.”

What ultimately happens to margins and cash generation will hinge on how one less visible pressure within that drug portfolio resolves.

That hidden pressure point is exactly where the full narrative for Johnson & Johnson steps in, laying out how Johnson & Johnson earnings could decouple if new therapies accelerate.

Seeking Alternatives Before The Crowd?

Fresh ideas tend to move first. Slow reactions can end up chasing momentum once prices are already moving quickly. Scan these focused stock lists while they are still under the radar and consider them before they become widely followed.

• Explore potential income opportunities early by scanning a curated set of high yield payers in the 5 dividend fortresses while they are still attracting less attention.

• Look for potential infrastructure candidates by checking the 39 power grid technology and infrastructure stocks while changes to energy networks are still developing and before they become more widely discussed.

• Monitor companies involved in automation by tracking operators in the 96 robotics and automation stocks before they receive broader attention in the market.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com